Zimmer Biomet marked a 1.1% change today, compared to -1.0% for the S&P 500. Is it a good value at today's price of $92.64? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
-
Zimmer Biomet belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 22.94 and an average price to book (P/B) of 3.19
-
The company's P/B ratio is 1.48
-
Zimmer Biomet has a trailing 12 month Price to Earnings (P/E) ratio of 20.6 based on its trailing 12 month price to earnings (EPS) of $4.5 per share
-
Its forward P/E ratio is 10.8, based on its forward earnings per share (EPS) of $8.6
-
Over the last four years, Zimmer Biomet has averaged free cash flows of $1.26 Billion, which on average grew 0.9%
-
ZBH's gross profit margins have averaged 11.7 % over the last four years and during this time they had a growth rate of 1.2 % and a coefficient of variability of 4674.42 %.
-
Zimmer Biomet has moved -20.4% over the last year compared to 9.4% for the S&P 500 -- a difference of -29.7%
-
ZBH has an average analyst rating of hold and is -14.71% away from its mean target price of $108.62 per share